Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.67 |
| ▸ | CA2 | P00918 | 6/20 | 0.67 |
| ▸ | CA12 | O43570 | 5/20 | 0.67 |
| ▸ | CA9 | Q16790 | 5/20 | 0.67 |
| ▸ | SUCNR1 | Q9BXA5 | 8/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439584 | 0.96 | CA1 (0.67) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL17974334 | 0.96 | CA12 (0.66) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL17987669 | 0.95 | CA12 (0.68) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL13185193 | 0.89 | CA12 (0.67) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL14811632 | 0.86 | CA12 (0.64) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL2610727 | 0.86 | CA12 (0.56) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL28030326 | 0.86 | CA12 (0.56) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL15672693 | 0.86 | CA12 (0.70) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL14812141 | 0.85 | CA1 (0.62) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL12461819 | 0.85 | CA12 (0.67) | CA1CA2CA12CA9SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140010762-A1 | IMAGING AGENTS | CHROMA THERAPEUTICS LTD (GB) | 2014-01-09 | — | — | US | disclosed |
| US-20140010762-A1 | IMAGING AGENTS | CHROMA THERAPEUTICS LTD (GB) | 2014-01-09 | — | — | US | disclosed |
| WO-2012080705-A1 | IMAGING AGENTS | CHROMA THERAPEUTICS LTD (GB) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140010762-A1 | IMAGING AGENTS | CES1, CES2, NCEH1 | CA1 50/4885CA2 175/4885CA12 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.